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Cardiac hypertrophyGATA4 has been characterized as a crucial regulator of cardiac development and hypertrophy. Multiple signaling
pathways involving MAPK contribute to GATA4 activation via direct phosphorylation. MSK and RSK are two
kinase families mediating signal transduction downstream of the MAPK cascade. In this study, we investigated
the effects of MSK and RSK on GATA4 activation. Overexpression of RSK2 greatly increased phosphorylation of
GATA4 at Ser261. This phosphorylation enhanced its transcriptional and DNA binding activity. RSK-dependent
phosphorylation of GATA4 also led to enhanced interaction with NKX2.5 and p300. Sequential phosphorylation
of the ERK–RSK–GATA4 cascade and nuclear accumulation of RSK in cardiomyocytes were observed after phen-
ylephrine treatment. Inhibition of RSK using the small molecule SL0101 abrogated GATA4 phosphorylation at
Ser261, ultimately leading to a repression of fetal cardiac genes. Adenovirus-mediated overexpression of MSK1
had no direct effect on GATA4 phosphorylation but increased GATA4 expression. Together with GATA4 phos-
phorylation at Ser105 by ERK1/2, our ﬁndings show dual phosphorylation of GATA4 by the ERK–RSK cascade
and suggest that MSK and RSK have distinct effects in PE-induced cardiac hypertrophic response.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
In response to mechanical load or neurohumoral insults the heart
undergoes hypertrophy, characterized by an increase in cell size, en-
hanced protein synthesis, fetal gene reactivation and remodeling.
Cardiac transcription factors are employed to promote hypertrophic
enlargement and fetal gene reactivation, and are profoundly involved
in cardioprotection from cytotoxic stress [1].
GATA4, a zinc ﬁnger transcription factor, was originally discovered
as a regulator of cardiac development and subsequently recognized as
a pivotal effector mediating cardiac gene transcription in response to
hypertrophic stimuli. GATA4 regulates gene transcription by binding
to GATA elements. Functional GATA regulatory sites have been iden-
tiﬁed within the promoters of multiple cardiac-speciﬁc genes, such
as myosin light chains, troponin C, troponin I, troponin C, atrial natri-
uretic factor (Anf), brain natriuretic peptide (Bnp), α-myosin heavy
chain (α-Mhc), and β-Mhc [2]. GATA4 alsomediates inducible gene ex-
pression in response to hypertrophic stimuli, including pressurec, β-myosin heavy chain; PE,
tein kinase; RSK, ribosomal S6
o-IP, coimmunoprecipitation;
c mobility-shift assay; ChIP,
@bjmu.edu.cn (C. Zhou).
l rights reserved.overload or neurohumoral insults. Targeted disruption of Gata4
emphasized its indispensable role in terminal differentiation of cardio-
myoblasts and survival of cardiac myocytes [3,4]. Overexpression of
Gata4 alone yielded features of cardiac hypertrophy both in cultured
cardiomyocytes and transgenic mice, including cell enlargement and
upregulated expression of fetal genes [5,6]. Expression of a dominant-
negative Gata4 or anti-sense Gata4 mRNA in cultured cardiomyocytes
blocked endothelin-1 and phenylephrine (PE)-induced hypertrophic
response [6].
GATA4 also serves as a survival factor by regulating expression of the
anti-apoptotic genes Bcl-2 and Bcl-xL as well as autophagy-related
genes [7–10]. Conditional deletion of GATA4 in young adulthood mice
led to cardiac dilation and heart failure associated with myocyte apo-
ptosis [11]. Overexpression of GATA4 antagonized cardiac myocyte apo-
ptosis and autophagy induced by oxidative stress and doxorubicin [8,9].
GATA4 was also found to be involved in erythropoietin-induced cardio-
protection against ischemia/reperfusion injury in the mouse heart [12].
Pro-apoptotic stimuli such as doxorubicin and ischemia/reperfusion
induced cardiotoxicity accompanied by downregulated expression
of GATA4 [13]. Hepatocyte growth factor protects cardiomyocytes
against apoptosis by triggering the activation of GATA4 through
MEK/ERK-dependent phosphorylation and upregulated Bcl-xL ex-
pression [7].
The activity of GATA4 is usually modulated through direct interac-
tion and post-translational modiﬁcations including phosphorylation,
acetylation and sumoylation [2]. GATA4 can be phosphorylated by
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endothelin-1 at Ser105, leading to increased transcriptional activity
[14–16]. ERKs preferentially targets GATA4 at Ser105 for phosphory-
lation, while p38 and JNK1 show only a minor effect. The RhoA/Rho
kinase (ROCK) pathway has been shown to be upstream of GATA4
phosphorylation by ERK and p38 MAPK in cardiomyocytes [17].
Some studies suggest that the PI3K/Akt/GSK3β pathway regulates
GATA4 but the precise phosphorylation sites on GATA4 are unknown
[18,19]. In gonadal cells, GATA4 can be phosphorylated by PKA at
Ser261 located in the two zinc ﬁngers that direct GATA4's binding
to the nucleotide sequence and mediate interaction with transcrip-
tional cofactors such as p300, MEF2C, SRF, Nkx2.5, NF-AT, and AP1
[20–23]. Thus, GATA4may function as a terminal integrator and effec-
tor in cardiac hypertrophy resulting from divergent cell signaling
pathways.
A subset of data support important roles for the MAPK signaling
pathway in cardiac hypertrophy. Three major MAPK family members
have been identiﬁed: ERK, JNK, and p38. It is well known that activat-
ed ERK and p38 isoforms can phosphorylate and activate GATA4.
However, it is unclear whether the protein kinases lying downstream
of MAPK cascades modulate GATA4 activity. Mitogen- and stress-
activated protein kinase (MSK) and ribosomal S6 kinase (RSK) consti-
tute a family of protein kinases that mediate signal transduction
downstream of MAPK cascades [24–26]. RSKs share 40% identity
with MSKs and the same overall structure. RSKs, consisting of four
isoforms, are activated by ERK cascades in response to growth factors,
peptide hormones, neurotransmitters and other stimuli. MSKs, com-
prising two members, can be activated by ERK and p38 kinases. Due
to a dual activation mode, MSKs can integrate mitogenic signals,
proinﬂammatory cytokines and cellular stress signals. MSK mRNAs
are ubiquitously expressed. Compared with Rsk1, which is highly
expressed in kidney and pancreas, Rsk2, 3 and 4 display strongest ex-
pression in heart and skeletal muscle [27]. The N-terminal kinase do-
main (NTK) of MSK and RSK kinases belongs to the AGC kinase family
and phosphorylates a wide range of substrates containing the con-
served motifs R/KxRxxS and RRxS (or RKS) [25]. When activated,
MSK and RSK can phosphorylate various nuclear proteins, including
histone H3, CREB, NFκB and other transcription factors. Previous re-
ports have revealed that MSK and RSK are activated in response to hy-
pertrophic agonists in cardiomyocytes [28–33]. The phosphorylation
of CREB stimulated by phenylephrine has been partly attributed to
MSK [30,31]. However, the precise effect of MSK and RSK in cardiac
hypertrophy is unknown.
In this paper we show that RSK, but not MSK, activates GATA4
through phosphorylation at Ser261. RSK2 greatly enhanced the tran-
scriptional activity of GATA4. Forced expression of RSK2 enhanced the
phosphorylation of GATA4 at Ser261, but MSK1 failed to activate
GATA4 in a similar way. The repression of RSK activity reduced
GATA4 phosphorylation and partly abolished the reactivation of car-
diac fetal genes in response to PE stimulation. Our ﬁndings reveal
an important mechanism for modulation of GATA4 by the ERK–RSK
cascade in cardiac hypertrophy.
2. Materials and methods
2.1. Cell culture
Neonatal rat ventricular myocytes (NRVMs) were prepared from
1- or 2-day-old SD rats as previously described [34]. The cells were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM, Gibco BRL)
supplemented with 15% fetal bovine serum for 48 h; the culture
media were then changed to serum-free medium and kept for anoth-
er 24 h before further experiments. The rat embryonic ventricular
myocardial cell line (H9c2) was purchased from the American Type
Culture Collection (Manassas, VA). Cells were cultured in DMEM con-
taining 1500 mg/L NaHCO3, supplemented with 10% fetal bovineserum. 293T and HEK-293 cells were maintained in DMEM supple-
mented with 10% fetal bovine serum.2.2. Materials
Phenylephrine was purchased from Sigma Aldrich (St. Louis, MO).
PD98059 was obtained from Promega (Madison, WI). SB203580, H89,
and SL0101 were purchased from Calbiochem (San Diego, CA). Anti-
bodies against NKX2.5, GATA4, phospho-GATA4 (Ser261), MSK1,
RSK2, and phospho-RSK1/2(Thr359/Ser363) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies speciﬁc for
ERK1/2, phospho-ERK1/2, histone H3, phospho-histone H3 (Ser10),
and phospho-MSK1 (Thr581) were supplied by Cell Signaling Tech-
nology (Beverly, MA). Antibodies against phospho-GATA4 (Ser105),
p300 and α-actinin were purchased from Abcam (Cambridge, United
Kingdom), Upstate Biotechnology (Lake Placid, NY), and Sigma Al-
drich, respectively.2.3. Plasmid constructs
Plasmids ANF-luc and β-MHC-luc were kindly provided by Dr.
Nemer M (Clinical Research Institute of Montreal, Montreal, Canada).
pFLAG-GATA4 was a gift from Dr. Molkentin JD (Department of Pedi-
atrics, University of Cincinnati, Cincinnati, Ohio). pCEFL-p38α and
pCMV-ERK1 plasmids were gifts from Drs. Engelberg D (The Hebrew
University of Jerusalem, Jerusalem, Israel) and Ma DL (Center for
Human Disease Genomics, Peking University). pRK5-RSK2 and
pGFP-RSK2 (WT and KD) were kindly provided by Dr. Huganir RL
(The Johns Hopkins University School of Medicine, Baltimore).
pKH3-RSK1 was kindly provided by John Blenis (Harvard Medical
School, Boston,). pCMV5-MSK1 (WT) and MSK1 dead kinase (MSK1
C-terminal kinase dead (CKD) and MSK1 N-terminal kinase dead
(NKD)) were kind gifts of Dr. Bourgeade MF. Mutants of GATA4
S105A and S261A were constructed using the QuickChange site-
directed mutagenesis kit (Stratagene, USA) according to the manufac-
turer's protocol with pFLAG-GATA4 as a template and conﬁrmed by
DNA sequencing. The following oligonucleotides and their respective
reverse complements were used for site-directed mutagenesis: S105A,
5′-ccgccgcccgtgGccccgcgcttctct-3′; S261A, 5′-cctcagcgccgcctgGccgcttcc
cgccggcc-3′ (mutant sites indicated in capital letters).2.4. Luciferase assays
H9c2 cells were seeded into 24-well plates 24 h before transfection.
Constructs noted in ﬁgure legends were transfected using Lipofecta-
mine2000 (Invitrogen) according to the manufacturer's instructions.
The total amount of DNAwas kept constant using pcDNA3.1/β-gal plas-
mid. The pRSVluc plasmid (Promega) was cotransfected as an internal
control. Luciferase activity was measured and normalized to Renilla lu-
ciferase activity. All experiments were done in triplicate and performed
at least three times.2.5. Coimmunoprecipitation (Co-IP)
Cells were lysed with low stringency buffer (50 mM Tris, pH 7.4,
150 mMNaCl, 0.5%NP40, 1 mMEDTA) plus complete protease inhibitor
cocktail (Roche). The soluble fraction was incubated overnight at 4 °C
with primary antibodies and subsequently protein G agarose beads
(Roche) were added to the solution and incubated for an additional
2 h at 4 °C. Beads were washed three times with lysis buffer, resus-
pended in SDS sample buffer, and boiled for 5 min. The eluted proteins
were resolved on SDS-PAGE and immunoblot analysis was performed.
584 T. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 582–5922.6. GST pull-down assays
GST-GATA4 fragment fusion proteins were expressed in BL21
Escherichia coli (E. coli) and puriﬁed according to standard protocols.
293T cells transfected with 10 μg of pRK5-RSK2 were lysed and lysates
were incubated overnight at 4 °C with puriﬁed GST proteins. Bound
proteins were separated by SDS-PAGE and subjected to Western blot-
ting using anti-GATA4 antibody.
2.7. Immunoblotting
Western blotting was performed as previously described [34]. Pro-
teins were separated by SDS-PAGE and transferred to nitrocellulose
membrane. For each analysis, the protein band of interest was visualized
through incubation with horseradish peroxidase-conjugated secondary
antibody and an ECL chemiluminescence detection kit (Vigorous, Beijing,
China). Band intensity from immunoblotting images was quantiﬁed by
Multi Gauge V3.0 (Fujiﬁlm, Japan).
2.8. Electrophoretic Mobility Shift Assays (EMSA)
Nuclear extracts were prepared from H9c2 cells or cardiomyocytes
treated as described previously [34]. Double-stranded oligonucleotides
for the Anf promoter containing GATA sites were designed and end-
labeled with [γ-32P] ATP. The sequences of the sense strand of oligonu-
cleotides are as follows: wild-type, 5′-gcttcgctggactgataactttaaaagg-3′;
mutant-type, 5′-gcttcgctggactactgactttaaaagg-3′.
2.9. Immunoﬂuorescence
NRVMs cultured on glass coverslips were ﬁxed in 3.7% (w/v) formal-
dehyde for 10 min. Indirect immunoﬂuorescent staining for α-actinin
(A7811, Sigma) was performed using FITC-conjugated secondary anti-
body to visualize cellular morphology. Fold changes in mean cell surface
area of α-actinin-immunostained cardiomyocytes (n≥50) were ana-
lyzed by Image tool software (Image-Pro Plus 5.0). For double-staining,
myocytes were identiﬁed by staining with antibodies against RSK2 and
phosphorylated histone H3 followed by secondary donkey anti-goat
and anti-rabbit IgG antibodies conjugated with ﬂuorescein isothiocya-
nate (FITC) or rhodamine (TRITC) (Santa Cruz). Nuclei were counter-
stained with Hoechst 33342 (Sigma) for 5 min at room temperature.
Immunoﬂuorescence was viewed under an Olympus FV1000 confocal
laser scanning microscope.
2.10. RNA extraction and RT-PCR
Total RNA isolation and RT-PCR were performed as previously de-
scribed [34]. Primers include: Anf 5′-ggctccttctccatcaccaa-3′ (forward)
and 5′-ctctgagacgggttgacttcc-3′ (reverse); β-Mhc 5′-gagtggacgttatt
gacttgg-3′ (forward) and 5′-gcctttctttgctttgccttt-3′ (reverse); Gapdh
5′-gtcagtggtggacctgacct-3′ (forward) and 5′-aggggagattcagtgtggtg-3′
(reverse).
2.11. Chromatin immunoprecipitation (ChIP) assay
1.6×107 cardiomyocytes were cross-linked with 1% formaldehyde
at 37 °C for 10 min, rinsed twice with ice-cold phosphate-buffered sa-
line and centrifuged for 5 min at 2000 g. Cells were then resuspended
in 0.2 mL of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris–Cl, pH 8.1)
and sonicated 12 times for 10 s each followed by centrifugation for
10 min. Reverse cross-linking and DNA puriﬁcation were performed
as described [34]. Both the input DNA and immunoprecipitated DNA
were detected by RT-PCR. The primers used for the Anf promoter
were 5′-aggcgagcgcccaggaagat-3′ (forward) and 5′-cggcggccaggagaa
gatgc-3′ (reverse).2.12. Construction of adenoviral vector encoding Msk1
The fragment encoding full-lengthMsk1was digested from pCMV5-
MSK1(WT) or pCMV5-MSK1(CKD) and inserted into pDC316 plasmid
(AGTC Gene Technology Company Ltd., Beijing, China). HEK-293 cells
were cotransfected with the shuttle plasmid pDC316-MSK1 and the
helper plasmid pBHGloxΔE1,3Cre. After showing the appearance typi-
cal of viral cytopathic effect, cells were collected followed by repeated
freezing and thawing to liberate virus. Control virusAd-EGFP is identical
to Ad-MSK1 (WT) except that it contains an Egfp expression cassette
rather thanMsk1.
2.13. Statistic analysis
The data are displayed as means±SD. Comparisons were analyzed
by Student's t-test or ANOVA. The signiﬁcance was analyzed with
SPSS10.0 software and a P-value b0.05 was considered to be statisti-
cally signiﬁcant.
3. Result
3.1. RSK2 augments GATA4-dependent transcription
MSK and RSK kinases lie downstream of MAPK cascades and may
exert versatile roles in cardiac hypertrophy. MSK is activated by ERK
and p38 kinases, and responds to cellular stress stimuli [25]. RSK is
predominantly activated by ERK and mediates intracellular signals
in response to growth factors and other stimuli [25]. GATA4, a crucial
transcriptional modulator of the cardiac disease response, receives
activating signals through phosphorylation events mediated by ERK,
PKA, AKT, and PKC kinases [2]. However, it is unknown whether
MSK and RSK activate GATA4. Thus, we performed transient transfec-
tion assays in H9c2 cardiomyoblast cells by cotransfecting GATA4 and
MSK1 or RSK2 in combination with cardiac speciﬁc promoters includ-
ing Anf and β-MHC reporters.
With the 638-bp Anf promoter, GATA4 alone gave a 4.0-fold acti-
vation. p38α, ERK1, MSK1, and RSK2 alone gave a 4.7, 5.2, 7.8 and
4.9-fold activation, respectively. Cotransfection of GATA4 with
p38α, ERK1, MSK1 or RSK2 produced a synergetic effect, enhancing
the GATA4-dependent activation of Anf promoter (Fig. 1A). The en-
hancing effects were not due to increases in GATA4 expression be-
cause the amount of GATA4 protein among all groups cotransfected
with GATA4 and different plasmids was approximately equal. Com-
pared with MSK1, RSK2 cotransfected with GATA4 exhibited a more
signiﬁcant synergistic effect, increasing Anf promoter activity 38.2-
fold over the basal promoter activity alone (Fig. 1A). In contrast,
MSK1 and GATA4 together gave 18.2-fold activation (Fig. 1A). Similar
results were also obtained from transient transfection with the
β-MHC promoter (Fig. 1B). Removal of −106/−135 bp from the Anf
promoter, which deleted the GATA4 binding sites, abolished the tran-
scriptional cooperation of GATA4 with MSK1 or RSK2 (Fig. 1D). These
results indicate MSK and RSK can enhance Anf promoter activation by
GATA4 without obvious effect on GATA4 protein levels.
In contrast, a dominant-defective form of RSK2 (KD) failed to coacti-
vate Anf promoter with GATA4, indicating intrinsic kinase activity of
RSK2 is required for cooperation (Fig. 1C). In addition, two dominant
negativemutants ofMSK1NKDand CKDdid not have any signiﬁcant ef-
fect on GATA4-mediated ANF activation (Fig. 1C). Therefore, we con-
clude that the kinase activities of MSK1 and RSK2 are essential for
cooperating with GATA4 to activate the Anf promoter.
3.2. RSK2 interacts with GATA4
Immunoprecipitation assays were performed to determine whether a
physical association exists between GATA4 andMSK1 or RSK2. As shown
in Fig. 2A, RSK2proteinwas detected in the complex immunoprecipitated
Fig. 1. Transcriptional effects of RSK2 and GATA4 on cardiac promoters. (A) and (B) The Anf and β-Mhc promoters can be transactivated by RSK2 and GATA4. H9c2 cells were transiently
transfectedwith the reporter constructs (0.2 μg), pRL-luc vector (20 ng) and pFLAG-GATA4 (0.4 μg) in combinationwith pCEFL-p38α, pCMV-ERK1, pCMV5-MSK1, or pRK5-RSK2 (0.8 μg).
pCDNA3.1/β-gal was used to keep the total amount of DNA constant. Forty-eight hours later, the relative ﬁreﬂy/renilla luciferase activity was determined. * Pb0.01 versus pFLAG-GATA4
alone. (C) Kinase activity is indispensable for RSK2 to stimulate the ANF-luc reporter with GATA4. The ANF-luc reporter (0.2 μg) was transfected into H9c2 cells with pFLAG-GATA4
(0.4 μg), and wild-type (WT) or dominant-negative mutants of pCMV5-MSK1 (NKD and CKD) and pGFP-RSK2 (KD) (0.8 μg) as indicated. (D) Deletion of the GATA4 binding sites
could reduce RSK2-induced activation of Anf promoter. The mutant pANF-luc (MT) was constructed by deleting the−106/−135 bp fragment from−638 bp ANF promoter, removing
the proximal GATA sites. Each bar represents mean±SD from 3 independent experiments, each sample in triplicate (* Pb0.01). In all the experiments above, cell lysates before luciferase
assay were also subjected to Western blotting using the anti-GATA4 and -GAPDH antibodies.
Fig. 2. RSK2 interacts with GATA4 in vivo and in vitro. (A) Cell lysates were prepared from H9c2 cells transfected with 8 μg of pCMV5-MSK1, or pRK5-RSK2 together with 4 μg of
pFLAG-GATA4 vector. Immunocomplex was precipitated with anti-GATA4 antibody. The immunoprecipitate was resolved by 10% SDS-PAGE, transferred to a nitrocellulose mem-
brane, and probed with anti-MSK1, anti-RSK2 or anti-GATA4 antibodies. (B) 300 μg of H9c2 cell lysate after transfection was immunoprecipitated with anti-MSK1, anti-RSK2 or
normal IgG as a control antibody, respectively. Immunoprecipitated GATA4 protein was detected by immunoblotting. (C) Identiﬁcation of the GATA4 domain that binds RSK2.
Bacterially-expressed GST fusion proteins with different fragments of GATA4 were bound to GSH-Sepharose and incubated with cell lysates from 293T cells transfected with
pRK5-RSK2 plasmid. After extensive washing, proteins retained by various GST fusions were analyzed together with 5% of the input material by Western blotting analysis using
anti-RSK2 antibody (middle panel). GST protein was used as a negative control. Structure and schematic diagrams of GST-GATA4 constructs are presented (top panel). N, Nf, Cf
and C stand for N terminal, N terminal zinc ﬁnger, C terminal zinc ﬁnger and C terminal domain, respectively. The bottom panel shows GST-fusion proteins stained by Coomassie
brilliant blue.
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GATA4 thus showing that a complex comprised of GATA4 and RSK2 can
be formed (Fig. 2B). However, no obvious interaction of MSK1 and
GATA4 was detected (Fig. 2A and B). To further map the interaction be-
tween GATA4 and RSK2, GST pull-down assays were performed. As
shown in Fig. 2C, the C-terminal zinc ﬁnger of GATA4 was the major do-
main interacting with RSK2. A weak interaction between the N-terminal
zinc ﬁnger of GATA4 and RSK2 was also seen. This direct interaction be-
tween GATA4 and RSK2 provides a molecular basis for the functional
synergy.
3.3. RSK2 enhances GATA4 phosphorylation at Ser261
Since RSK2 can interact with GATA4, we investigated whether
RSK2 phosphorylates GATA4. It is well-known that RSK generally
phosphorylates serine residues in variations of the motifs RRxS and
RKS. A highly conserved serine residue of GATA4 matching the RRxS
motif is located at position 261 (Ser261) (referring to rat species;
this is at position 262 in mice), which was previously reported as aFig. 3. RSK2 facilitates GATA4 phosphorylation at Ser261. (A) H9c2 cells were cotransfected w
Rsk2 genes as depicted. 40 h after transfection, cells were subjected to serum-free medium
performedwith anti-phospho-GATA4 (Ser105), anti-phospho-GATA4 (Ser261), anti-GATA4 (to
to induce the phosphorylation of GATA4 at Ser261. (C) Cotransfection with pKH3-RSK1 also i
pFLAG-GATA4 and pCMV-ERK1 plasmids. Inhibition of endogenous activities of RSK kinases w
GATA4 at Ser261. (E) GATA4 phosphorylation at Ser261 was detected in H9c2 cells transfect
and S261A) GATA4 as depicted. (F) H9c2 cells were transiently transfected with either wild
pRK5-RSK2 to estimate Anf promoter activity. Each bar represents mean±SD from 3 independpredominant phosphoacceptor site targeted by PKA [23]. Therefore,
we performed a cotransfection assay followed by Western blotting
to test the effect of RSK2 on GATA4 phosphorylation in H9c2 cells.
Overexpression of RSK2 speciﬁcally induced GATA4 phosphorylation
at Ser261 with a very weak effect on Ser105 phosphorylation
(Fig. 3A). The dominant-defective form of RSK2 (KD) failed to phos-
phorylate GATA4 at Ser261 (Fig. 3B). In addition, we observed that
RSK1 also induced GATA4 phosphorylation at Ser261 (Fig. 3C). In
comparison, ERK1 transfection promoted GATA4 phosphorylation at
both serine residues while p38α and MSK1 had a minor effect
(Fig. 3A). RSK inhibitor (SL0101) attenuated phosphorylation of
GATA4 at Ser261 even when ERK1 was overexpressed, indicating
that the endogenous kinase activity of RSK is indispensable for
ERK1-induced GATA4 phosphorylation at Ser261 (Fig. 3D). The
GATA4 S261A mutant (with replacement of serine by alanine at resi-
due 261) was not detectable by anti-phospho-GATA4 (Ser261), con-
ﬁrming the speciﬁcity of the antibody (Fig. 3E). Interestingly,
mutation of Ser105 also attenuated phosphorylation of GATA4 at
Ser261, implying phosphorylation at Ser105 by ERK1/2 facilitatesith 1 μg of pFLAG-GATA4 and 2 μg of different vectors encoding β-gal, p38α, Erk1,Msk1, or
for 8 h to inhibit endogenous activities of MAP kinases. Western blotting analysis was
tal) antibodies. (B) Cotransfectionwith the dominant-negativemutant of RSK2 (KD) failed
nduced the phosphorylation of GATA4 at Ser261. (D) H9c2 cells were cotransfected with
ith SL0101 (50 μM) for 8 h before cell lysis attenuated ERK1-induced phosphorylation of
ed with pRK5-RSK2 in combination with either wild-type (WT) or mutant-type (S105A
-type or mutant GATA4 constructs in combination with pCMV-ERK1, pCMV5-MSK1, or
ent experiments, each sample in triplicate (* Pb0.01).
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GATA4 S261A mutant exhibited a lower efﬁciency than wild-type in
activating the Anf promoter, especially in conditions of overexpression
of ERK1or RSK2 kinases (Fig. 3F).Meanwhile, RSK2 still greatly increased
the transcriptional activity of GATA4 S105A mutant (Fig. 3F). We com-
bined these results with previous studies on GATA4 phosphorylation at
Ser105 by ERK1/2, and raised a two-step phosphorylation model for
GATA4 activationmediated by ERK–RSK cascade. ERK1/2 phosphorylates
GATA4 at Ser105, and then RSK activated by ERK1/2 phosphorylates
GATA4 at Ser261.
3.4. RSK2 enhances GATA4's afﬁnity with DNA
The two zinc ﬁngers of GATA4 have been shown to direct GATA4
binding with target DNA element. EMSA assay was performed to
examine the effect of RSK2 on the DNA binding abilities of GATA4.
Cold wild-type probe competition and supershift experiments with
speciﬁc antibody conﬁrmed the speciﬁcity of GATA4 binding
(Fig. 4A). An equal amount of nuclear extract prepared from H9c2
cells transfected with GATA4 was mixed with those overexpressing
p38α, ERK1, MSK1, or RSK2, and probed with a radiolabeled oligonu-
cleotide containing GATA site. As shown in Fig. 4B, RSK2 greatly
enhanced the DNA binding activity of wild-type GATA4 with a higher
potency than ERK1, but the effect of p38α and MSK1 seemed to be
weak. Meanwhile, RSK2 also facilitated the DNA binding activity of
GATA4 S105A mutant, but was unable to stimulate S261A mutant
(Fig. 4D). The DNA binding activity of GATA4 was markedly reduced
after H9c2 cells were treated with PD98059 (MEK inhibitor) or
SL0101 (RSK inhibitor) (Fig. 4C). SB203580 (p38 inhibitor) failed to
completely abrogate the binding of GATA4with DNA. A speciﬁc inhib-
itor of MSK, H89 also yielded a negative effect probably owing to its
additional inhibition of PKA kinase. Thus, we conclude that RSK2-
mediated GATA4 phosphorylation leads to a high afﬁnity for DNA
element.
3.5. RSK2 enhances the interaction of GATA4 with NKX2.5 and p300
It is well known that GATA4 physically cooperates with transcrip-
tion associated proteins to activate the cardiac gene program throughFig. 4. RSK2 enhances the DNA binding activity of GATA4. (A) Nuclear extracts from H9c2 cells
containing a conserved GATA site from the Anf proximal promoter. Supershift EMSA with a spe
the retarded bands represent the interaction of the probeswith GATA4 protein (lanes 2–3). Com
of GATA4 (lanes 4–5). (B) Nuclear extracts from H9c2 cells overexpressing β-gal, p38α, ERK1
GATA4 as indicated and incubated with the radio-labeled probe for 30 min before electrop
SB203580, 20 μMPD98059, 10 μMH89, 50 μM SL0101) for 8 h after transfection with pFLAG-G
extracts fromH9c2 cells transfectedwithmutant-type (S105A and S261A) GATA4 plasmidswe
subjected to EMSA assay.its zinc ﬁnger domains. NKX2.5 and p300 are important proteins that
interact with GATA4 [20–22]. To examine whether RSK-mediated
GATA4 phosphorylation modulates the physical interaction with
NKX2.5 and p300, H9c2 cells were cotransfected with either β-gal,
RSK2 (WT), or RSK2 (KD) in addition to NKX2.5/p300 and GATA4
plasmids. Nuclear extracts from these cells were subjected to immu-
noprecipitation with anti-GATA4 antibody. As shown in Fig. 5A and
B, an interaction of GATA4 with NKX2.5 or p300 was observed in
wild-type RSK2-containing extracts compared with β-gal-containing
extracts. Conversely, RSK2 (KD) reduced the p300/GATA4 and
NKX2.5/GATA4 interaction. To exclude the effect that RSK exerts on
NKX2.5 and p300, immunoprecipitations with wild-type and mutant
GATA4 were performed. As shown in Fig. 5C and D, GATA4 S261A
mutant displayed a greatly decreased afﬁnity with NKX2.5 and
p300, especially when RSK2 was overexpressed. We performed
these immunoprecipitation and Western blotting experiments at
least four times and found the results to be reproducible. They dem-
onstrate that RSK-mediated GATA4 phosphorylation allows for stron-
ger recruitment and cooperation with other transcriptional factors
and cofactors via its zinc ﬁnger domains.
3.6. PE stimulates RSK activation in cardiomyocytes
Subsequently, we wanted to know the association between RSK2
and GATA4 in cardiomyocytes. PE, an α1-adrenoceptor agonist, is
often used to treat NRVMs to mimic cardiac hypertrophy. The activa-
tion of multiple kinases was determined by immunoblotting with
antibodies speciﬁc for the phosphorylated forms of each kinase after
exposure to PE over a 5–60 min period. Speciﬁcally, PE rapidly acti-
vated ERK1/2, stimulating a maximal response within 5 min, declin-
ing rapidly after that and reaching basal levels by 30 min (Fig. 6A).
ERK pathway generally activates RSK2 by phosphorylation, leading
to autophosphorylation of RSK2 at multiple sites. Exposure of
NRVMs to PE also increased phosphorylation of RSK2, coinciding tem-
porally with ERK1/2 activation (Fig. 6A). RSKs are usually present in
the cytoplasm as well in the nucleus. Upon activation, a fraction of
activated RSKs enter the nucleus, and this translocation correlates
with the expression of inducible genes. Accompanied by increased
phosphorylation of RSK2, signiﬁcant nuclear accumulation of RSK2overexpressing GATA4were probedwith a radiolabeled double-stranded oligonucleotide
ciﬁc antibody against GATA4 or a non-related antibody (normal goat IgG) conﬁrmed that
petition EMSA further demonstrated that the retarded band represented speciﬁc binding
, MSK1, or RSK2, respectively, were mixed with equal amounts of those overexpressing
horesis. (C) Nuclear extracts from H9c2 cells treated with different inhibitors (10 μM
ATA4were subjected to EMSA to estimate the DNA binding activity of GATA4. (D) Nuclear
remixed as indicatedwith equal amounts of those overexpressing RSK2 protein, and then
Fig. 5. RSK2modulates the interaction of GATA4with NKX2.5 and p300. (A) and (B) H9c2 cells were cotransfectedwith 6 μg ofwild-type ormutant-type pGFP-RSK2 in addition to 3 μg of
pFLAG-GATA4 and 3 μg of pFLAG-NKX2.5 (A) or 9 μg of pCMV-p300 (B), as depicted. pCDNA3.1/β-galwas used to keep the total amount of DNA constant. Cell lysates prepared from these
cells were immunoprecipitated with anti-GATA4 antibody or control IgG. After SDS-PAGE; the immunoprecipitates were subjected to Western blotting using speciﬁc antibodies against
GATA4, NKX2.5 or p300. 5% of immunoprecipitatewas used as input to illustrate the equal level of GATA4 used for pull-down. (C) and (D) H9c2 cells were cotransfectedwith 3 μg ofwild-
type ormutant-type GATA4 in addition to 6 μg of pRK5-RSK2 and 3 μg of pFLAG-NKX2.5 (C) or 9 μg of pCMV-p300 (D), as depicted. Immunoprecipitationwas performedwith anti-GATA4
antibody or control IgG followed by Western blotting using antibodies against NKX2.5 or p300.
588 T. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 582–592was observed (Fig. 6D). In comparison, a rapid increase in MSK1
phosphorylation was observed at 5 min, and this was sustained up
to 60 min (Fig. 6A). The activation of RSK and MSK usually elicits
dynamic phosphorylation of histone H3 followed by chromatin remo-
deling including histone acetylation and activation of inducible genes.
Therefore, we assessed phosphorylation of histone H3. Upon stimula-
tion, phosphorylation of histone H3 at Ser10 was slowly elevated
(maximal 2.1-fold increase) and remained so for a considerable
time after the onset of stimulation (Fig. 6C). Data from immunocyto-
ﬂuorescence assay conﬁrmed nuclear histone H3 underwent phos-
phorylation of Ser10 after stimulation (Fig. 6D).
In parallel with the activation of ERK1/2 and RSK2, enhanced phos-
phorylated GATA4 in a time-dependent manner was recognized by
anti-Ser105 or anti-Ser261 antibodies, respectively (Fig. 6B). It indicates
that Ser261 phosphorylation is important for the hypertrophic respon-
siveness of GATA4 as Ser105. Thus, we conﬁrm the involvement of
phosphorylated RSK2 and GATA4 in PE-induced hypertrophy.
3.7. SL0101 inhibits PE-stimulated GATA4 activation mediated by RSK
We next investigated the effects of inhibitors blocking the activity
of ERK1/2 and RSK2 on GATA4 activation and cardiac hypertrophy.
Prior treatment of NRVMs with PD98059 (20 μM), a speciﬁc MEK in-
hibitor, resulted in the complete inhibition of RSK2 phosphorylation
and prevented the phosphorylation of GATA4 protein at Ser105 andSer261 (Fig. 7A). Incubation of NRVMs with 50 μM SL0101 abolished
phosphorylation of GATA4 at Ser261, while having no obvious inhibito-
ry effect on phosphorylation of GATA4 at Ser105 (Fig. 7A). Conversely,
adenovirus-mediated overexpression of MSK1 did not directly alter
the phosphorylation of GATA4 at Ser261 while augmenting the expres-
sion of GATA4, indicating a speciﬁc effect of MSK1 involved in cardiac
hypertrophy (Fig. 7B). Thus, ourﬁndings further support a link between
ERK–RSK cascade and GATA4 phosphorylation.
The hypertrophy marker genes, Anf and β-Mhc, contain GATA reg-
ulatory binding sites in their promoters. Further experiments demon-
strated pretreatment with PD98059 or SL0101 markedly repressed
the elevated expression of Anf and β-Mhc in response to PE, and at-
tenuated the increased recruitment of GATA4 and RSK2 on Anf pro-
moter (Fig. 7C and D). EMSA assay suggested PE-induced increase in
GATA's DNA binding activity was also inhibited by PD98059 and
SL0101 (Fig. 7E). The recruitment of RSK2 onto inducible gene pro-
moters may trigger phosphorylation of histone H3, which usually fa-
vors other covalent modiﬁcations such as acetylation. Therefore, we
subsequently investigated the effect of PE and speciﬁc kinase inhibi-
tors on histone H3 modiﬁcations. PE increased the phosphorylation
and acetylation status of histone H3 on Anf promoter while this effect
was partly attenuated by PD98059 and SL0101 (Fig. 7D). In compari-
son with SL0101, PD98059 exerted an inhibitory effect with a higher
efﬁcacy, which may result from more extensive downstream
substrates of ERK kinases than RSK. We also detected increased
Fig. 6. RSK2 and GATA4 phosphorylation is involved in PE-induced hypertrophy. (A) NRVMs were exposed to 10 μM PE for the times indicated. Cell extracts were subjected toWestern
blottingwith speciﬁc antibodies for phospho-ERK1/2, phospho-RSK, or phospho-MSK1. Cardiomyocytes culturedwithout PE were used as a control. (B)Western blotting showedGATA4
phosphorylation at Ser105 and Ser261 upon PE stimulation. (C)Western blotting showed phosphorylation of histone H3 (Ser10) upon PE stimulation. Total and phosphorylated histone
H3 were quantiﬁed by densitometric scanning and the ratio of phosphorylated/total histone H3 was plotted (lower panel). The results are expressed as mean±SD from three
independent experiments. Pb0.05, versus the control group, cells untreated by PE. (D) NRVMs were exposed to 10 μM PE for 15 min, immobilized and subjected to immunoﬂuorescence
using antibodies against phosphorylated histone H3 (Ser10) or RSK2.
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RSK2may be recruited onto the Anf promoter by GATA4 as a molecular
scaffold via direct interaction and contribute to chromatin remodeling
and the building of transcriptional machinery. NRVMs stimulated by
PE displayed an increase in cell size which was also partly reduced by
PD98059 (Pb0.01) and SL0101 (Pb0.05) (Fig. 7E). Taken together, our
results indicate that RSK2 is involved in fetal gene reprogramming dur-
ing the hypertrophic response via modulating GATA4 phosphorylation.4. Discussion
In this study we revealed RSK2, a downstream kinase of ERK cas-
cade, is involved in GATA4 activation in cardiomyocytes. GATA4 has
been recognized as a critical regulator mediating the hypertrophic re-
sponse. Overexpression of a dominant-negative GATA4 or anti-sense
GATA4 mRNA abrogated the PE-induced increase in cell size and hy-
pertrophic gene expression [3,4]. GATA4 evoked by PE is coupled
with phosphorylation at serine 105 by ERK1/2 and p38 kinases, lead-
ing to a marked increase in transactivating and DNA binding activity
[14–16]. Our results further indicate that RSK2 stimulated by ERK cas-
cade promotes phosphorylation of GATA4 at Ser261.RSKs constitute a family of Ser/Thr kinases that lie downstream of
the Ras–MEK–ERK cascade. RSKs have been implicated in the regula-
tion of diverse cellular processes, including cell proliferation, survival,
growth and motility, via phosphorylating downstream cytosolic and
nuclear targets. Though Rsk1-4 is expressed ubiquitously in many tis-
sues, the levels of Rsk2-4 are relatively high in heart although the pre-
cise role of RSKs in the heart has not been fully elucidated [27].
Genetic deletion and mutations of Rsk2 gene have been linked to Cof-
ﬁn–Lowry syndrome (CLS), an X-linked disease characterized by
mental retardation, short stature and skeletal anomalies. Valve mal-
formation and congestive heart failure can occur in patients with
the syndrome, indicating a role for Rsk2 in heart development and
function [35]. RSKs can be activated by neurohumoral stimuli, me-
chanical stretch and chronic pressure overload [28,29,33]. Prostaglan-
din E2-stimulated expression of brain natriuretic peptide and c-fos in
cardiomyocytes was blocked by either ERK1/2 or RSK inhibition.
These ﬁndings established a link between RSK and cardiac gene
expression and cardiac hypertrophy [29].
In this paper, we demonstrate that GATA4 is a substrate for RSK2-
mediated phosphorylation. RSK2 facilitated GATA4-dependent trans-
activation, whereas dominant-defective mutant of RSK2 lost this
activity. Furthermore, a physical association of RSK2 and GATA4 was
Fig. 7. Inhibition of RSK kinases attenuates GATA4 phosphorylation mediated by PE. (A) NRVMs were either left untreated or pre-incubated with PD98059 (20 μM) or SL0101
(50 μM) for 30 min. Then they were incubated with or without PE (10 μM) for 15 min. Cell extracts were separated by SDS-PAGE and the phosphorylation statuses of ERK1/2,
RSK, and GATA4 were detected by immunoblotting. (B) The expression and phosphorylation statuses of GATA4 from NRVMs infected by Ad-EGFP, Ad-MSK1 (WT), or Ad-MSK1
(CKD) were analyzed by immunoblotting. (C) NRVMs were treated as described above. Total RNA was then extracted and mRNA encoding Anf, β-Mhc, and Gapdh was detected
using RT-PCR. (D) ChIP assay was performed with cell lysates from NRVMs treated as depicted above with speciﬁc antibodies or normal IgG as a control. Input DNA was used as
a template to determine whether equal amounts of total DNA were used in each group. (E) NRVMs were pre-incubated with PD98059 (20 μM) or SL0101 (50 μM) for 30 min before
PE stimulation. Equal amounts of nuclear extract from NRVMs treated by PE for 15 min were subjected for EMSA to evaluate the DNA afﬁnity of GATA4. (F) NRVMs were cultured
with PE (10 μM) in combination with PD98059 (20 μM) or SL0101 (50 μM) for 48 h and then stained with α-actinin antibody for immunoﬂuorescence to exhibit cell size. NRVMs
cultured without PE were used as a control (Con). Surface area measurements were performed on α-actinin-stained cardiomyocytes (n≥50). The relative area normalized to the
control group was analyzed (* Pb0.01 vs. PE group, # Pb0.05 vs. PE group).
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increase in phosphorylation of GATA4 at Ser261 was detected upon
forced-expression of RSK2. It further suggests that GATA4 may be a
downstream substrate of RSK kinase. Though ERK1 can elevate
GATA4 phosphorylation at Ser261 in vivo, previous study indicated
that ERK did not efﬁciently phosphorylate GATA4 outside the
N-terminal domain in vitro. Additionally, MAP kinases prefer to phos-
phorylate sequences containing a PXSP or PXXSPmotif [25]. We specu-
lated RSK kinases may serve as a mediator in ERK-induced GATA4
phosphorylation at Ser261. Our results support a model that GATA4undergoes dual phosphorylation at Ser105 and Ser261 triggered by
ERK cascade in response to PE stimulation, and RSK contributes to
GATA4 phosphorylation at Ser261. Multiple phosphorylations may
be seen in some precedents. In melanocytes, MAPK signaling trig-
gered two phosphorylation events on Mi activation mediated by
ERK at Mi Ser73 and by RSK at Ser409 respectively [36]. Because
Ser261 is located between the two zinc ﬁngers of GATA4 DNA-
binding domain, which are important for cofactor recruitment and
DNA afﬁnity, we hypothesize that RSK-mediated GATA4 phosphory-
lation at Ser261 plays a vital role in transactivation of GATA4,
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tion assays. Meanwhile, RSK2 is also involved in chromatin remo-
deling, cooperating with GATA4 in reactivation of fetal genes such
as Anf.
Owing to broad substrate speciﬁcity, RSK may exert versatile effects
on cardiac function through other mechanisms. Besides GATA4, other
RSK substrates have been implicated in cardiac hypertrophy, including
CREB, SRF, NFATc4, NFAT3 and IκBα/NFκB [24]. RSK is also known to
phosphorylate GSK3β, a negative regulator of GATA4, and thereby
inhibit its kinase activity [37]. Additionally, RSK can contribute to
transcriptional induction via phosphorylation of histone H3 on Ser10
and Ser28 of some inducible genes. RSK also phosphorylates TSC2 and
eIF4B, thereby promoting mTOR signaling and protein synthesis
[38,39]. Cardiac cMyBP-C and cTnI are RSK substrates which indicate a
role of RSK in regulating cardiacmyoﬁlament function [40,41]. Interest-
ingly, individual RSK isoforms may couple to different substrates, exhi-
biting redundancy or opposing effects in the same biological event. For
instance, Rsk1 and 2 beneﬁt cell outgrowth whereas Rsk3 and 4 may
function as potential tumor suppressor to inhibit cell proliferation and
colony formation [24]. Given the diverse effects of RSKs, more studies
analyzing individual isoform function in the heart are necessary.
AlthoughMSKs and RSKs are structurally similar kinases, there are
some differences in their respective activation mechanisms and bio-
logical roles. In contrast to RSKs directly activated by ERK kinases,
MSKs are activated by both the ERK and p38 pathways. It is noted
that MSK1 is not capable of phosphorylating GATA4 at Ser261 but
can increase the expression of GATA4 in cardiomyocytes. Though
MSK1 also shows transcriptional cooperation with GATA4, we did
not detect a direct interaction between GATA4 and MSK1. With re-
gard to the regulation of GATA4's DNA binding activity, MSK1 is infe-
rior to RSK2. Thus, we speculate that MSK1 may indirectly affect
GATA4-dependent transcription. In fact, activated MSK kinases are
known to phosphorylate and activate a number of transcription fac-
tors associated with the cardiac gene program, including CREB,
NFκB, SRF, and Elk-1 [26]. MSK1 also contributes to the upregulation
of the immediate early gene c-jun during PE-induced cardiac hyper-
trophy [31]. Furthermore, the transactivation capacity of CBP/p300
is also enhanced by activated MSK1 [42]. It is plausible that these co-
factors activated by MSK1 can converge with GATA4 to modify the
cardiac hypertrophic response. Combined with the strong preference
of ERK rather than p38 or JNK kinases for the phosphorylation of
GATA4 at Ser105, we assume that the ERK–RSK cascade is more high-
ly specialized for controlling the dual phosphorylations of GATA4 at
Ser105 and Ser261 than the p38-MSK cascade. However, our data
do not exclude a potential role for the p38-MSK cascade in the phos-
phorylation of GATA4 at other sites.
Cardiac hypertrophy may initially represent an adaptive response
to improve cardiac pump function. When the pathological stimuli are
severe and prolonged, it ultimately progresses to contractile dysfunc-
tion predisposing to heart failure, arrhythmia and sudden death.
GATA4 is an important transcription factor mediating cardiac hyper-
trophy. Overexpression of GATA4 in cardiomyocytes directly results
in a striking hypertrophic phenotype characterized by fetal gene reac-
tivation coupled with increased sarcomeric organization, protein syn-
thesis and cell size. Transgenic overexpression of GATA4 in heart
further veriﬁes the sufﬁciency of GATA4 in cardiac hypertrophy
[5,6]. Meanwhile, GATA4 promotes cardiac adaptation following
pathologic stimulation by regulating cell survival and angiogenic pro-
gram [2]. GATA4 is required for the adaptive and antiapoptotic
responses of the heart during the progression of hypertrophy. In
this paper, our data emphasize the importance of the ERK cascade
in GATA4 regulation, but not the p38 cascade. It underscores a precise
mechanism for the role of ERK cascade in the adaptive or protective
response after hypertrophic stimuli.
Studies have revealed different roles for the three branches of the
MAPK signaling pathway in the pathological development of cardiacdiseases and disorders. Mounting evidence suggests that activation
of the Raf–MEK–ERK cascade mediates cardiac hypertrophy, particu-
larly by contributing to the increased length of myocytes, but also
protects the heart from cell death and ischemic injury [43–46]. It
seems that ERK cascade constitutes an important adaptive and pro-
tective mechanism in the heart, conferring cardioprotection against
ischemia–reperfusion injury and apoptosis after pressure overload.
In contrast, p38 and JNK kinases function as transducers of stress re-
sponse, markedly activated by pressure or volume overload. Activa-
tion of p38 and JNK cascades also provoke hypertrophic responses
including speciﬁc gene expression and increase in protein synthesis.
On the contrary, p38 and JNK kinases antagonize the growth of indi-
vidual cardiomyocytes and promote contractile dysfunction, myocyte
loss, cardiac remodeling and ﬁbrosis [43–46]. In addition, the positive
effect of ERK–RSK cascade on the control of cardiac contractility is
counteracted by simultaneous activation of p38 kinase [47]. Taken to-
gether, p38 and JNK cascades have been thought to be associated with
various pathological conditions in the heart such as hypertrophy,
extracellular matrix remodeling and cardiac decompensation. There-
fore, we speculate that the ERK rather than the p38 cascade is special-
ized in regulating GATA4 with respect to the cardiac adaptive
response. Supporting evidence can be found in the way that hepato-
cyte growth factor evokes the activation of GATA4 through the
MEK–ERK cascade and then upregulated Bcl-xL expression [7].
Thus our data highlights a novel mechanism whereby the ERK–
RSK cascade activates GATA4 via dual phosphorylations. It represents
a possible event involved in fetal gene reactivation and the adaptive
response of cardiac hypertrophy, and maintaining cardiac gene ex-
pression in differentiating/adult heart. Further investigation is re-
quired to determine the role of the ERK–RSK–GATA4 cascade in
other physiological and pathological conditions, and it may provide
a potential therapeutic approach for cardiac diseases.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This work was supported by the National Natural Sciences Foun-
dation of China (30871253, 90919022, 31101057), the 111 Project
of China (B07001) and the Sciences Foundation of Zhejiang Normal
University (ZC304009172).
References
[1] T. Oka, J. Xu, J.D. Molkentin, Re-employment of developmental transcription
factors in adult heart disease, Semin. Cell Dev. Biol. 18 (2007) 117–131.
[2] Y.J. Suzuki, Cell signaling pathways for the regulation of GATA4 transcription factor:
implications for cell growth and apoptosis, Cell. Signal. 23 (2011) 1094–1099.
[3] C.T. Kuo, E.E. Morrisey, R. Anandappa, K. Sigrist, M.M. Lu, M.S. Parmacek, C.
Soudais, J.M. Leiden, GATA4 transcription factor is required for ventral morpho-
genesis and heart tube formation, Genes Dev. 11 (1997) 1048–1060.
[4] J.D. Molkentin, Q. Lin, S.A. Duncan, E.N. Olson, Requirement of the transcription
factor GATA4 for heart tube formation and ventral morphogenesis, Genes Dev.
11 (1997) 1061–1072.
[5] F. Charron, G. Tsimiklis, M. Arcand, L. Robitaille, Q. Liang, J.D. Molkentin, S.
Meloche, M. Nemer, Tissue-speciﬁc GATA factors are transcriptional effectors of
the small GTPase RhoA, Genes Dev. 15 (2001) 2702–2719.
[6] Q. Liang, L.J. De Windt, S.A. Witt, T.R. Kimball, B.E. Markham, J.D. Molkentin, The
transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in
vitro and in vivo, J. Biol. Chem. 276 (2001) 30245–30253.
[7] K. Kitta, R.M. Day, Y. Kim, I. Torregroza, T. Evans, Y.J. Suzuki, Hepatocyte growth
factor induces GATA-4 phosphorylation and cell survival in cardiac muscle cells,
J. Biol. Chem. 278 (2003) 4705–4712.
[8] S. Kobayashi, T. Lackey, Y. Huang, E. Bisping, W.T. Pu, L.M. Boxer, Q. Liang,
Transcription factor gata4 regulates cardiac BCL2 gene expression in vitro and in
vivo, FASEB J. 20 (2006) 800–802.
[9] S. Kobayashi, P. Volden, D. Timm, K. Mao, X. Xu, Q. Liang, Transcription factor
GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death,
J. Biol. Chem. 285 (2010) 793–804.
592 T. Li et al. / Biochimica et Biophysica Acta 1823 (2012) 582–592[10] Y.J. Suzuki, H. Nagase, C.M. Wong, S.V. Kumar, V. Jain, A.M. Park, R.M. Day, Regu-
lation of Bcl-xL expression in lung vascular smooth muscle, Am. J. Respir. Cell Mol.
Biol. 36 (2007) 678–687.
[11] T. Oka, M. Maillet, A.J. Watt, R.J. Schwartz, B.J. Aronow, S.A. Duncan, J.D.
Molkentin, Cardiac-speciﬁc deletion of Gata4 reveals its requirement for hyper-
trophy, compensation, and myocyte viability, Circ. Res. 98 (2006) 837–845.
[12] X. Shan, X. Xu, B. Cao, Y. Wang, L. Guo, Q. Zhu, J. Li, L. Que, Q. Chen, T. Ha, C. Li, Y. Li,
Transcription factor GATA-4 is involved in erythropoietin-induced cardioprotec-
tion against myocardial ischemia/reperfusion injury, Int. J. Cardiol. 134 (2009)
384–392.
[13] Y.J. Suzuki, H. Nagase, R.M. Day, D.K. Das, GATA-4 regulation of myocardial surviv-
al in the preconditioned heart, J. Mol. Cell. Cardiol. 37 (2004) 1195–1203.
[14] R. Kerkela, S. Pikkarainen, T. Majalahti-Palviainen, H. Tokola, H. Ruskoaho,
Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcrip-
tion factor-mediated regulation of B-type natriuretic peptide gene, J. Biol. Chem.
277 (2002) 13752–13760.
[15] Q. Liang, R.J. Wiese, O.F. Bueno, Y.S. Dai, B.E. Markham, J.D. Molkentin, The
transcription factor GATA4 is activated by extracellular signal-regulated kinase
1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes, Mol. Cell.
Biol. 21 (2001) 7460–7469.
[16] O. Tenhunen, B. Sarman, R. Kerkela, I. Szokodi, L. Papp, M. Toth, H. Ruskoaho,
Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-
induced activation of GATA-4 binding in adult heart, J. Biol. Chem. 279 (2004)
24852–24860.
[17] T. Yanazume, K. Hasegawa, H. Wada, T. Morimoto, M. Abe, T. Kawamura, S.
Sasayama, Rho/ROCK pathway contributes to the activation of extracellular
signal-regulated kinase/GATA-4 during myocardial cell hypertrophy, J. Biol.
Chem. 277 (2002) 8618–8625.
[18] B. Chandrasekar, S. Mummidi, W.C. Claycomb, R. Mestril, M. Nemer, Interleukin-
18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol
3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway
in cardiomyocytes, J. Biol. Chem. 280 (2005) 4553–4567.
[19] C. Morisco, K. Seta, S.E. Hardt, Y. Lee, S.F. Vatner, J. Sadoshima, Glycogen synthase
kinase 3beta regulates GATA4 in cardiac myocytes, J. Biol. Chem. 276 (2001)
28586–28597.
[20] Y.S. Dai, P. Cserjesi, B.E. Markham, J.D. Molkentin, The transcription factors
GATA4 and dHAND physically interact to synergistically activate cardiac gene
expression through a p300-dependent mechanism, J. Biol. Chem. 277 (2002)
24390–24398.
[21] Y.S. Dai, B.E. Markham, p300 Functions as a coactivator of transcription factor
GATA-4, J. Biol. Chem. 276 (2001) 37178–37185.
[22] D. Durocher, F. Charron, R. Warren, R.J. Schwartz, M. Nemer, The cardiac
transcription factors Nkx2-5 and GATA-4 are mutual cofactors, EMBO J. 16
(1997) 5687–5696.
[23] J.J. Tremblay, R.S. Viger, Transcription factor GATA-4 is activated by phosphorylation
of serine 261 via the cAMP/protein kinase a signaling pathway in gonadal cells,
J. Biol. Chem. 278 (2003) 22128–22135.
[24] R. Anjum, J. Blenis, The RSK family of kinases: emerging roles in cellular
signalling, Nat. Rev. Mol. Cell Biol. 9 (2008) 747–758.
[25] C. Hauge, M. Frodin, RSK and MSK in MAP kinase signalling, J. Cell Sci. 119 (2006)
3021–3023.
[26] L. Vermeulen, W. Vanden Berghe, I.M. Beck, K. De Bosscher, G. Haegeman, The
versatile role of MSKs in transcriptional regulation, Trends Biochem. Sci. 34
(2009) 311–318.
[27] M. Zeniou, T. Ding, E. Trivier, A. Hanauer, Expression analysis of RSK gene family
members: the RSK2 gene, mutated in Cofﬁn–Lowry syndrome, is prominently
expressed in brain structures essential for cognitive function and learning,
Hum. Mol. Genet. 11 (2002) 2929–2940.
[28] R.R. Baliga, D.R. Pimental, Y.Y. Zhao, W.W. Simmons, M.A. Marchionni, D.B.
Sawyer, R.A. Kelly, NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-
kinase, p70(S6K), and MEK-MAPK-RSK, Am. J. Physiol. 277 (1999) H2026–H2037.[29] Q. He, P. Harding, M.C. LaPointe, PKA, Rap1, ERK1/2, and p90RSK mediate PGE2
and EP4 signaling in neonatal ventricular myocytes, Am. J. Physiol. Heart Circ.
Physiol. 298 (2010) H136–H143.
[30] T. Markou, D. Cieslak, C. Gaitanaki, A. Lazou, Differential roles of MAPKs and MSK1
signalling pathways in the regulation of c-Jun during phenylephrine-induced
cardiac myocyte hypertrophy, Mol. Cell. Biochem. 322 (2009) 103–112.
[31] T. Markou, M. Hadzopoulou-Cladaras, A. Lazou, Phenylephrine induces activation
of CREB in adult rat cardiac myocytes through MSK1 and PKA signaling pathways,
J. Mol. Cell. Cardiol. 37 (2004) 1001–1011.
[32] J. Sadoshima, Z. Qiu, J.P. Morgan, S. Izumo, Angiotensin II and other hypertrophic
stimuli mediated by G protein-coupled receptors activate tyrosine kinase,
mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The
critical role of Ca(2+)-dependent signaling, Circ. Res. 76 (1995) 1–15.
[33] Y. Takeishi, Q. Huang, J. Abe, M. Glassman, W. Che, J.D. Lee, H. Kawakatsu, E.G.
Lawrence, B.D. Hoit, B.C. Berk, R.A. Walsh, Src and multiple MAP kinase activation
in cardiac hypertrophy and congestive heart failure under chronic pressure-
overload: comparison with acute mechanical stretch, J. Mol. Cell. Cardiol. 33
(2001) 1637–1648.
[34] C.G. Zhang, Z.Q. Jia, B.H. Li, H. Zhang, Y.N. Liu, P. Chen, K.T. Ma, C.Y. Zhou, beta-
Catenin/TCF/LEF1 can directly regulate phenylephrine-induced cell hypertrophy
and Anf transcription in cardiomyocytes, Biochem. Biophys. Res. Commun. 390
(2009) 258–262.
[35] M.M. Massin, M.A. Radermecker, A. Verloes, S. Jacquot, T. Grenade, Cardiac
involvement in Cofﬁn–Lowry syndrome, Acta Paediatr. 88 (1999) 468–470.
[36] M. Wu, T.J. Hemesath, C.M. Takemoto, M.A. Horstmann, A.G. Wells, E.R. Price, D.Z.
Fisher, D.E. Fisher, c-Kit triggers dual phosphorylations, which couple activation
and degradation of the essential melanocyte factor Mi, Genes Dev. 14 (2000)
301–312.
[37] C. Sutherland, I.A. Leighton, P. Cohen, Inactivation of glycogen synthase kinase-3
beta by phosphorylation: new kinase connections in insulin and growth-factor
signalling, Biochem. J. 296 (Pt 1) (1993) 15–19.
[38] P.P. Roux, B.A. Ballif, R. Anjum, S.P. Gygi, J. Blenis, Tumor-promoting phorbol
esters and activated Ras inactivate the tuberous sclerosis tumor suppressor
complex via p90 ribosomal S6 kinase, Proc. Natl. Acad. Sci. U. S. A. 101 (2004)
13489–13494.
[39] D. Shahbazian, P.P. Roux, V. Mieulet, M.S. Cohen, B. Raught, J. Taunton, J.W.
Hershey, J. Blenis, M. Pende, N. Sonenberg, The mTOR/PI3K and MAPK pathways
converge on eIF4B to control its phosphorylation and activity, EMBO J. 25
(2006) 2781–2791.
[40] F. Cuello, S.C. Bardswell, R.S. Haworth, E. Ehler, S. Sadayappan, J.C. Kentish, M.
Avkiran, Novel role for p90 ribosomal S6 kinase in the regulation of cardiac
myoﬁlament phosphorylation, J. Biol. Chem. 286 (2011) 5300–5310.
[41] S. Itoh, B. Ding, C.P. Bains, N. Wang, Y. Takeishi, T. Jalili, G.L. King, R.A. Walsh, C.
Yan, J. Abe, Role of p90 ribosomal S6 kinase (p90RSK) in reactive oxygen species
and protein kinase C beta (PKC-beta)-mediated cardiac troponin I phosphoryla-
tion, J. Biol. Chem. 280 (2005) 24135–24142.
[42] R. Janknecht, Regulation of the ER81 transcription factor and its coactivators by
mitogen- and stress-activated protein kinase 1 (MSK1), Oncogene 22 (2003)
746–755.
[43] I. Kehat, J.D. Molkentin, Extracellular signal-regulated kinase 1/2 (ERK1/2)
signaling in cardiac hypertrophy, Ann. N. Y. Acad. Sci. 1188 (2010) 96–102.
[44] K. Lorenz, J.P. Schmitt, M. Vidal, M.J. Lohse, Cardiac hypertrophy: targeting
Raf/MEK/ERK1/2-signaling, Int. J. Biochem. Cell Biol. 41 (2009) 2351–2355.
[45] A.J. Muslin, MAPK signalling in cardiovascular health and disease: molecular
mechanisms and therapeutic targets, Clin. Sci. (Lond.) 115 (2008) 203–218.
[46] A. Rohini, N. Agrawal, C.N. Koyani, R. Singh, Molecular targets and regulators of
cardiac hypertrophy, Pharmacol. Res. 61 (2010) 269–280.
[47] I. Szokodi, R. Kerkela, A.M. Kubin, B. Sarman, S. Pikkarainen, A. Konyi, I.G. Horvath, L.
Papp, M. Toth, R. Skoumal, H. Ruskoaho, Functionally opposing roles of extracellular
signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the
regulation of cardiac contractility, Circulation 118 (2008) 1651–1658.
